Figure 5
From: Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia
Isobologram analyses of combined dual PI3K/MTOR plus TKI treatment in mutant-TK activated leukemia cells. Co-treatment of specific TKI (sunitinib to target FLT3 ITD in MOLM14 cells (A and C), imatinib to target BCR-ABL1 in K562 cells (B and D) with either NVP-BGT226 (A and B) or NVP-BEZ235 (C and D) reveal additive to synergistic proapoptotic effects for the combination treatment: Isobolograms are provided, showing experimental points that fall on or below the predicted line of additive effect, indicating additive to superadditive effects for all tested endpoints. Calculations of combination indices (CI) provide a mathematical number to describe the degree of synergy for the respective endpoint.